Skip to main content
. 2019 Dec 13;25:9517–9523. doi: 10.12659/MSM.918126

Figure 2.

Figure 2

Kaplan-Meier event-free survival curves and serum calprotectin levels in patients with diabetes who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Patients with lower serum calprotectin levels had a significantly improved 12-month major adverse cardiovascular event (MACE)-free survival compared with patients with higher serum calprotectin levels (P=0.01).